Cornea/External Disease News

Harrow announced it will begin marketing and selling Vigamox, a fluoroquinolone antibiotic eye drop for bacterial conjunctivitis, following completion of the product’s new drug application transfer.

Verséa Ophthalmics will distribute Celularity’s Biovance and Biovance 3L Ocular products for ocular surface disease treatment and ocular surgical support under the terms of an exclusive U.S. commercialization agreement.

Children with Cogan’s syndrome should undergo thorough evaluations upon presentation, including screenings for autoimmune and infectious diseases, as well as echocardiography and brain MRI, according to data.

Verséa Ophthalmics announced the distribution of its T-POC Total IgE Immunoassay Kit, a tear-based point-of-care test for the diagnosis and management of ocular surface disease.

A new automated marketing platform aimed at helping eye care providers manage dry eye disease is now available from Hoot Health Inc.

The FDA approved Xdemvy, a 0.25% lotilaner ophthalmic solution, for the treatment of Demodex blepharitis, according to a press release from Tarsus Pharmaceuticals.

We should talk a bit about evaporative dry eye disease.

Do you need to hit the brakes to stop a car that is already in park? Probably not. That’s the idea behind the indication for cross-linking to treat progressive keratoconus. A patient who has stopped progressing doesn’t need to be treated.

Harrow announced that it signed agreements with Santen Pharmaceutical Co. affiliates to acquire their branded ophthalmic portfolio and also with Novaliq GmbH to acquire Vevye.

Sequential custom therapeutic keratectomy proved effective in the treatment of granular corneal dystrophy type 1, leading to long-term vision improvement and reduction of astigmatism and higher-order aberrations, according to a study.